Pacira BioSciences Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
829
- Stock Symbol
-
PCRX
- Investments
-
14
- Share Price
-
$36.47
- (As of Friday Closing)
Pacira BioSciences General Information
Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Contact Information
Website
www.pacira.comCorporate Office
- 5401 West Kennedy Boulevard, Lincoln Center
- Suite 890
- Tampa, FL 33609
- United States
Corporate Office
- 5401 West Kennedy Boulevard, Lincoln Center
- Suite 890
- Tampa, FL 33609
- United States
Pacira BioSciences Timeline
Pacira BioSciences Stock Performance
As of 13-Nov-2026, Pacira BioSciences’s stock price is $36.47. Its current market cap is $1.46B with 39.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $36.47 | $36.46 | $18.80 - $36.66 | $1.46B | 39.9M | 1.29M | $0.94 |
Pacira BioSciences Financials Summary
As of 30-Sep-2026, Pacira BioSciences has a trailing 12-month revenue of $743M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,159,626 | 1,292,365 | 1,060,517 | 1,921,916 |
| Revenue | 743,301 | 726,411 | 700,966 | 674,978 |
| EBITDA | 123,528 | 99,771 | 9,429 | 143,141 |
| Net Income | 37,727 | 7,034 | (99,560) | 41,955 |
| Total Assets | 1,202,639 | 1,264,917 | 1,553,516 | 1,574,386 |
| Total Debt | 340,280 | 418,204 | 638,853 | 586,044 |
Pacira BioSciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pacira BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pacira BioSciences Comparisons
Industry
Financing
Details
Pacira BioSciences Competitors (23)
One of Pacira BioSciences’s 23 competitors is Noven Pharmaceuticals, a Corporate Backed or Acquired company based in Miami, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Noven Pharmaceuticals | Corporate Backed or Acquired | Miami, FL | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Audion Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
Pacira BioSciences Patents
Pacira BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025208569-A1 | Manufacturing of bupivacaine multivesicular liposomes | Pending | 20-May-2024 | ||
| EP-4673147-A1 | Manufacturing of bupivacaine multivesicular liposomes | Pending | 20-May-2024 | ||
| GB-2644950-A | Manufacturing of bupivacaine multivesicular liposomes | Pending | 20-May-2024 | ||
| GB-2644950-A8 | Manufacturing of bupivacaine multivesicular liposomes | Pending | 20-May-2024 | ||
| US-12156940-B1 | Manufacturing of bupivacaine multivesicular liposomes | Active | 20-May-2024 | A61K31/445 |
Pacira BioSciences Signals
Pacira BioSciences Investments & Acquisitions (14)
Pacira BioSciences’s most recent deal was a Merger/Acquisition with GQ Bio Therapeutics for . The deal was made on 27-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GQ Bio Therapeutics | 27-Feb-2025 | Merger/Acquisition | Drug Discovery | ||
| Kineta (Certain Assets in Seattle, Washington) | 10-Feb-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Spine BioPharma | 11-Oct-2023 | Later Stage VC | Drug Discovery | ||
| CarthroniX | 22-Apr-2022 | Later Stage VC | Drug Discovery | ||
| Genascence | 07-Jan-2022 | Later Stage VC | Biotechnology |
Pacira BioSciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.63 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Pacira BioSciences Exits (4)
Pacira BioSciences’s most recent exit was on 02-Dec-2021 from Coda Biotherapeutics. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Coda Biotherapeutics | 02-Dec-2021 | Completed |
|
||
| Iovera | 09-Apr-2019 | Completed |
|
||
| TELA Bio | 25-Oct-2017 | Completed |
|
||
| TELA Bio | 27-Jan-2017 | Early Stage VC | Completed |
|
Pacira BioSciences Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| GQ Bio Therapeutics | Hamburg, Germany | 2012 |
Pacira BioSciences FAQs
-
When was Pacira BioSciences founded?
Pacira BioSciences was founded in 2006.
-
Where is Pacira BioSciences headquartered?
Pacira BioSciences is headquartered in Tampa, FL.
-
What is the size of Pacira BioSciences?
Pacira BioSciences has 829 total employees.
-
What industry is Pacira BioSciences in?
Pacira BioSciences’s primary industry is Pharmaceuticals.
-
Is Pacira BioSciences a private or public company?
Pacira BioSciences is a Public company.
-
What is Pacira BioSciences’s stock symbol?
The ticker symbol for Pacira BioSciences is PCRX.
-
What is the current stock price of Pacira BioSciences?
As of 13-Nov-2026 the stock price of Pacira BioSciences is $36.47.
-
What is the current market cap of Pacira BioSciences?
The current market capitalization of Pacira BioSciences is $1.46B.
-
What is Pacira BioSciences’s current revenue?
The trailing twelve month revenue for Pacira BioSciences is $743M.
-
Who are Pacira BioSciences’s competitors?
Noven Pharmaceuticals, Pfizer (Vienna), Pfizer Pakistan, Audion Therapeutics, and Gilead are some of the 23 competitors of Pacira BioSciences.
-
What is Pacira BioSciences’s annual earnings per share (EPS)?
Pacira BioSciences’s EPS for 12 months was $0.94.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process